|
|
|
| Dec. 24, 2002 |
Court Dismisses Amgen Reimbursement Challenge
|
| Dec. 23, 2002 |
Amgen Submits Data To FDA Supporting Once-Weekly Dosing Of Enbrel
|
| Dec. 23, 2002 |
FDA Approves Enbrel Manufacturing Facility; Supply For Patients Dramatically Increases
|
| Dec. 9, 2002 |
Data From Study Shows Aranesp Dosed Every Other Week More Cost-Effective Than Epoetin Alfa For Treating Anemia In Chemotherapy Patients
|
| Dec. 5, 2002 |
Amgen Announces Results Of Phase 3 Study Of Enbrel Dosed Once Weekly
|
| Dec. 4, 2002 |
Amgen Announces Webcast Of Conference Call To Provide Financial Guidance For 2003
|
| Dec. 2, 2002 |
Enbrel Offered To Additional 40,000 Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis And Psoriatic Arthritis Patients
|
| Nov. 15, 2002 |
Amgen Files Suit Seeking Relief From Reimbursement Ruling
|
| Nov. 13, 2002 |
Serono And Amgen Sign License Agreement For Multiple Sclerosis Product
|
| Nov. 5, 2002 |
Amgen Business Review Meeting Resheduled To February 25, 2003
|
| Nov. 3, 2002 |
First-In-Class Oral Calcimimetic Shown To Reduce Parathyroid Hormone Levels In Chronic Kidney Disease
|
| Nov. 3, 2002 |
New Data On Aranesp(R) Dosed Every Other Week In Anemic Chronic Kidney Disease Patients Presented At 35th Annual Meeting Of The American Society Of Nephrology
|
| Nov. 3, 2002 |
First-In-Class Oral Calcimimetic Shown To Reduce Parathyroid Hormone Levels In Chronic Kidney Disease
|
| Oct. 31, 2002 |
Amgen Comment On New OPPS Rule
|
| Oct. 25, 2002 |
Enbrel(R) Only TNF Receptor With Five Years Sustained Data In Treatment Of Rheumatoid Arthritis
|
| Oct. 25, 2002 |
Enbrel(R) Is First Therapy Shown To Inhibit Bone And Joint Damage In Psoriatic Arthritis Patients
|
| Oct. 25, 2002 |
AMGEN ANNOUNCES POSITIVE STUDY RESULTS OF KINERET(R) IN RHEUMATOID ARTHRITIS DISEASE PROGRESSION AND IN THE TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
|
| Oct. 24, 2002 |
ENBREL(R) FIRST THERAPY SUBMITTED TO FDA SHOWING INHIBITION OF BONE AND JOINT DAMAGE IN PSORIATIC ARTHRITIS PATIENTS
|
| Oct. 23, 2002 |
Amgen's Third Quarter 2002 Adjusted Earnings Per Share Increase 13% To 34 Cents
|
| Oct. 22, 2002 |
AMGEN FILES WITH FDA FOR USE OF KINERET(R) TO INHIBIT BONE AND JOINT DAMAGE DUE TO RHEUMATOID ARTHRITIS
|
| Oct. 18, 2002 |
Amgen Wins Arbitration and Awarded $150 Million Against Johnson & Johnson
|
| Oct. 17, 2002 |
Amgen And Wyeth Pharmaceuticals Announce Initiation Of Landmark Study In Rheumatoid Arthritis
|
| Oct. 9, 2002 |
Amgen Announces Webcast Of Third-Quarter 2002 Financial Results
|
| Sep. 26, 2002 |
Amgen Submits Data To FDA Supporting Use Of Enbrel To Improve Physical Function In Rheumatoid Arthritis Patients
|
| Aug. 29, 2002 |
Rob Lowe Introduces One-To-One Support Network For New Cancer Patients
|
| Aug. 23, 2002 |
Amgen Announces Filing With FDA For Licensure Of Enbrel Production Facility In Rhode Island
|
| Jul. 24, 2002 |
Second Quarter 2002 Earnings Per Share Increase 27 Percent To 38 Cents
|
| Jul. 22, 2002 |
FDA Approves Amgen's Aranesp For Anemia Associated With Chemotherapy
|
| Jul. 19, 2002 |
Amgen Announces Webcast of Second-Quarter 2002 Financial Results
|
| Jul. 16, 2002 |
Amgen Completes Acquisition Of IMMUNEX
|
| Jun. 12, 2002 |
Amgen Announces $2 Billion Stock Repurchase Plan
|
| Jun. 3, 2002 |
Amgen Receives CPMP Recommendation For European Union Marketing Approval Of Neulasta For The Reduction Of Chemotherapy - Induced Neutropenia
|
| Jun. 3, 2002 |
Amgen Receives CPMP Positive Recommendation For European Union Regulatory Approval Of Aranesp(R)n Oncology
|
| May. 31, 2002 |
Amgen Announces Its Registration Statement on Form S-3 Has Been Declared Effective
|
| May. 22, 2002 |
Amgen Files Registration Statement In Connection With Its Zero-Coupon Convertible Notes
|
| May. 21, 2002 |
Aranesp Studies Explore Potential Of New Anemia Treatment Paradigms
|
| May. 16, 2002 |
Amgen Stockholders Approve Issuance of Shares in Connection with Immunex Acquisition
|
| May. 10, 2002 |
Hassan Dayem Will Join Amgen as Senior Vice President and Chief Information Officer
|
| May. 8, 2002 |
Important Drug Warning Counterfeiting of Epogen(R)
|
| May. 8, 2002 |
Amgen to Acquire Filgrastim and Pegfilgrastim in Europe from Roche
|
| Apr. 25, 2002 |
Amgen Reports First Quarter 2002 Earnings Per Share Increased 14 Percent to 32 Cents
|
| Apr. 22, 2002 |
2002 Recipients of Amgen Award for Science Teaching Excellence Announced (California)
|
| Apr. 22, 2002 |
2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Jefferson County, Kentucky)
|
| Apr. 22, 2002 |
2002 Recipients of Amgen Award for Science Teaching Excellence Announced (Boulder County, Colorado)
|
| Apr. 22, 2002 |
Rob Lowe Launches Awareness Campaign About One Of The Most Dangerous And Unrecognized Side Effects Of Chemotherapy -- Infections
|
| Apr. 12, 2002 |
Amgen Announces Webcast of First-Quarter 2002 Financial Results
|
| Mar. 14, 2002 |
Amgen Signs Multi-Year Agreement With US Oncology for Aranesp, Neulasta and NEUPOGEN
|
| Mar. 14, 2002 |
Amgen Signs Multi-Year Agreement With International Oncology Network for Aranesp, Neulasta and NEUPOGEN
|
| Mar. 13, 2002 |
European Commission Approves Amgen's Kineret for the Treatment of Rheumatoid Arthritis; First Interleukin-1 Receptor Antagonist Represents New Way to Treat RA
|
| Feb. 27, 2002 |
Multimedia Available: What's Your AQ? -- Anemia Quotient --
|
| Feb. 27, 2002 |
Multimedia Available: Actor Danny Glover Joins Anemia LifeLine to Help Millions of Americans Who Suffer From Anemia Associated With Serious Diseases
|
| Feb. 27, 2002 |
Actor Danny Glover Joins Anemia LifeLine(TM) to Help Millions of Americans Who Suffer from Anemia Associated with Serious Diseases
|
| Feb. 22, 2002 |
Amgen to Receive $2.5 Billion From Offering of Zero-Coupon Senior Convertible Notes
|
| Feb. 21, 2002 |
Amgen to Raise $2.5 Billion From Offering of Zero-Coupon Senior Convertible Notes
|
| Feb. 6, 2002 |
Amgen and Immunex Receive Request for Additional Information From The Federal Trade Commission
|
| Feb. 4, 2002 |
The United States Pharmacopeia Accepts Amgen's Aranesp for Treatment of Chemotherapy-Associated Anemia
|
| Feb. 1, 2002 |
UPDATE: FDA Approves Amgen's Neulasta for Serious and Frequent Chemotherapy Side Effect
|
| Jan. 31, 2002 |
Multimedia Available: FDA Approves Amgen's Neulasta for Serious & Frequent Chemotherapy Side Effect
|
| Jan. 31, 2002 |
FDA Approves Amgen's Neulasta for Serious and Frequent Chemotherapy Side Effect
|
| Jan. 23, 2002 |
Amgen Reports Fourth Quarter and Full Year 2001 Financial Results in Line With Guidance
|
| Jan. 15, 2002 |
Amgen Announces Webcast of Fourth-Quarter and Full Year 2001 Financial Results
|
| Jan. 11, 2002 |
Amgen Announces Award for Science Teaching Excellence; First Year Focusing on Science Teaching
|
| Jan. 10, 2002 |
Amgen Appoints Beth Seidenberg as Senior Vice President -- Development
|
| Jan. 10, 2002 |
Amgen Announces Award for Science Teaching Excellence in California; First Year Focusing on Science Teaching; A Statewide Call for Nominations
|
| Jan. 8, 2002 |
Frank Biondi Joins Amgen's Board of Directors
|
| Jan. 8, 2002 |
Patricia Sueltz Elected to Amgen's Board of Directors
|
|
|
|
|
|
|
|
|
|
|
|
